Roche pays $184M to snag mtm diagnostics ops

Demonstrating once again that it's willing to invest in diagnostics, Roche has inked a deal to buy mtm laboratories for €130 million down with another €60 million promised in milestones. The German company develops in vitro diagnostics, specializing in the detection and diagnosis of cervical cancer. Roche has been spending heavily on diagnostics, putting its money where its mouth is in pursuit of more personalized therapies. Story

Suggested Articles

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.